Clinical trials: Adapted Physical Activity, open to volunteers
- Condition Adapted Physical Activity
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Advanced Squamous Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy…
- Trial name
- NCT07241039
- Testing
- ABBV-711, Budigalimab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- AbbVie
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Crohn's Disease
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world.
- Trial name
- NCT06023030
- Where
- 104 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white…
- Trial name
- REVIVAL (NCT07581002)
- Testing
- Pivekimab Sunirine, Venetoclax, Azacitidine
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 660 people
- Sponsor
- AbbVie
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Multiple Myeloma
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- NCT07095452
- Testing
- Etentamig, Lenalidomide, Daratumumab
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 680 people
- Sponsor
- AbbVie
Multiple Myeloma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in…
- Trial name
- NCT06896916
- Testing
- Etentamig, Iberdomide
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Neovascular Age-related Macular Degeneration
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina.
- Trial name
- NCT07007065
- Testing
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Where
- 138 sites in United States, Austria and 15 more
- Volunteers
- 561 people
- Sponsor
- AbbVie
Bipolar I Disorder, Bipolar II Disorder
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- NCT06696755
- Testing
- Icalcaprant
- Where
- 33 sites in United States
- Volunteers
- 195 people
- Sponsor
- AbbVie
Ventral Hernia
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems.
- Trial name
- NCT07226791
- Testing
- AGN-151607-DP
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia (CLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration…
- Trial name
- ReVenG (NCT04895436)
- Testing
- Venetoclax, Obinutuzumab
- Where
- 58 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- AbbVie
Amyloid Light Chain (AL) Amyloidosis
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Amyloid light chain (AL) amyloidosis is a rare disease caused by abnormal plasma cells producing misfolded light chain proteins that deposit in organs, leading to organ dysfunction and failure.
- Trial name
- NCT07793422
- Testing
- Etentamig, Daratumumab, Cyclophosphamide
- Volunteers
- 370 people
- Sponsor
- AbbVie
Ovarian Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
- Trial name
- NCT07278336
- Testing
- ABBV-901, Bevacizumab, Carboplatin
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 285 people
- Sponsor
- AbbVie
Chronic Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other…
- Trial name
- NCT06810505
- Testing
- Atogepant
- Where
- 66 sites in United States, Canada and 9 more
- Volunteers
- 420 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care.
- Trial name
- NCT07044687
- Testing
- Venetoclax, Azacitidine
- Where
- 14 sites in India
- Volunteers
- 100 people
- Sponsor
- AbbVie
Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult…
- Trial name
- NCT06953960
- Testing
- Surzetoclax, Daratumumab, Dexamethasone
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Upper Limb Essential Tremor
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating.
- Trial name
- NCT07673107
- Testing
- AGN-151607-DP
- Where
- 21 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- AbbVie
Immunoglobulin Light Chain (AL) Amyloidosis
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma…
- Trial name
- NCT06158854
- Testing
- ABBV-383 (Etentamig)
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- AbbVie
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube…
- Trial name
- NCT07769502
- Testing
- Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Non-Squamous Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab…
- Trial name
- NCT07005102
- Testing
- Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi)
- Where
- 65 sites in United States, Australia and 11 more
- Volunteers
- 854 people
- Sponsor
- AbbVie